Vir Biotechnology (VIR) Income from Continuing Operations (2018 - 2026)
Vir Biotechnology (VIR) reported Income from Continuing Operations of 125695000.0 for Q1 2026, down 3.91% on a YoY basis from 130809959.78 in Q1 2025, and down 192.84% sequentially from 42923000.0 in Q4 2025.
Vir Biotechnology (VIR) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Vir Biotechnology (VIR) has 9 years of Income from Continuing Operations data on file, last reported at 125695000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 3.91% year-over-year to 125695000.0; the trailing twelve-month figure through Mar 2026 stood at 442717000.0 (up 23.36% YoY), and the FY2025 full-year result was 437987000.0, up 16.09% from the prior year.
- Income from Continuing Operations eased to 125695000.0 in Q1 2026, from 42923000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 518621000.0 in Q1 2022 to a low of 213717000.0 in Q3 2024.
- A 5-year average of 69701294.12 and a median of 115973000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 407.04% in 2022, while the deepest fall reached 223.75% in 2022.
- Tracing VIR's Income from Continuing Operations over 5 years: stood at 101603000.0 in 2022, then retreated by 14.14% to 115973000.0 in 2023, then gained by 9.82% to 104589000.0 in 2024, then surged by 58.96% to 42923000.0 in 2025, then plunged by 192.84% to 125695000.0 in 2026.
- Business Quant data shows VIR's Income from Continuing Operations at 125695000.0 in Q1 2026, 42923000.0 in Q4 2025, and 163141000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Vir Biotechnology | 1.38 Bn | 1.38 Bn | - | -125.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -125.70 Mn |
| Dec 31, 2025 | -42.92 Mn |
| Sep 30, 2025 | -163.14 Mn |
| Jun 30, 2025 | -110.96 Mn |
| Mar 31, 2025 | -120.97 Mn |
| Dec 31, 2024 | -104.59 Mn |
| Sep 30, 2024 | -213.72 Mn |
| Jun 30, 2024 | -138.38 Mn |
| Mar 31, 2024 | -65.28 Mn |
| Dec 31, 2023 | -115.97 Mn |
| Sep 30, 2023 | -163.41 Mn |
| Jun 30, 2023 | -194.78 Mn |
| Mar 31, 2023 | -140.96 Mn |
| Dec 31, 2022 | -101.60 Mn |
| Sep 30, 2022 | 175.31 Mn |
| Jun 30, 2022 | -76.49 Mn |
| Mar 31, 2022 | 518.62 Mn |
| Dec 31, 2021 | 525.25 Mn |
| Sep 30, 2021 | 110.43 Mn |
| Jun 30, 2021 | 61.81 Mn |